Objective. To evaluate current opioid prescribing patterns nationally and regionally across several northern New England states and compare with prescription data on an institutional level over a twoyear period, between 2013 and 2014.
Introduction
Opioid use for chronic noncancer pain first began to escalate in the late 1990s. Increased public demand for better medical management of pain led the Federation of State Medical Boards to publish a position statement in 1998, which suggested that barriers to opioid prescribing may be contributing to "unnecessary patient suffering" [1] . State medical boards subsequently lessened restrictions on physicians prescribing opioids. In 2000, the Joint Commission on the Accreditation of Health Care Organizations (JCAHO) acknowledged pain as the "5th vital sign" (a term coined by former American Pain Society President Dr. James Campbell in 1995), acknowledging that undertreated pain led to poorer outcomes and increased health care expenditure [2] . Liberalization of opioid prescribing followed suit, bolstered by weak but published evidence of opioid analgesic safety in chronic noncancer pain [3] [4] [5] [6] , aggressive marketing of opioid analgesics by pharmaceutical companies [7] , and an increased public awareness of the right to pain relief. While initially unrecognized, this increased access to opioid analgesics developed into what is currently referred to by the Centers for Disease Control and Prevention (CDC) as an epidemic of opioid abuse and dependence [8] .
Between 2000 and 2009, the number of US opioid prescriptions per 100 persons grew by 35%, while the average size of an oxycodone and hydrocodone prescriptions in morphine milligram equivalents (MME) increased by nearly 70% [9] . MME here was calculated based on equianalgesic dose calculations previously established by Gordon et al. [10] . In 2010, enough opioid prescriptions were filled to medicate every American with 5 mg of hydrocodone every four hours for an entire month [11] . Rates of prescription opioid misuse, abuse, and death have risen in tandem [12, 13] . Opioids were responsible for one death every 36 minutes in the United States in 2008 and are now responsible for more injury-related deaths than motor vehicle collision and suicide combined, or cocaine-and heroin-related deaths combined [8] .
Current evidence suggests that the analgesic efficacy of opioids in noncancer pain may be limited to acute management, with long-term effectiveness being unclear and potentially wrought with undesired side effects such as hyperalgesia, physical dependence, tolerance, and respiratory depression [14] [15] [16] . Duration of opioid consumption has been associated with increasing prevalence of psychological distress, unhealthy lifestyles, and increased health care utilization [17] .
Concerns about the impact of the opioid epidemic on public health have prompted government and physician organizations to develop initiatives, programs, and services to address the issue. Newer research suggests that progress is being made, with opioid prescriptions reaching a plateau in 2011-13 [18, 19] , alongside lower rates of abuse and diversion [18] . This study reviews opioid prescription data from a home institution of Dartmouth Hitchcock Medical Center over the first and last quarters of a two-year period, 2013-14. Comparisons were made with data from a geographically similar academic institution (University of Vermont Medical Center), as well as benchmark data from a database of opioid prescriptions filled nationally and in adjacent northern New England states (MA, ME, VT, NH). Interstate differences in safe opioid initiatives were highlighted, with the hypothesis that states with robust strategies to reduce opioid overdose may see larger declines in opioid prescribing.
Methods
Our study compared opioid usage between two time periods: January-June 2013 and July-December 2014. Data for total retail prescriptions for noninjectable opioids, all payer types, were obtained from the IMS Health National Prescription Audit (NPA) database [20] . This is a rolling two-year database; as such, the study interval was chosen to allow for the largest timespan achievable with the data set. The NPA database contains pharmacy records from over 37,000 retail pharmacies across the continental United States, Alaska, and Hawaii. This includes independent pharmacies, chain pharmacies, pharmacies in discount outlets, and pharmacies in food stores. It captures approximately 74% of prescription data and projects approximately 26%.
Opioid utilization was reviewed nationally and in adjacent northern New England states of New Hampshire, Vermont, Maine, and Massachusetts via the NPA database. State-wide prescription data were identified by zip code of the provider. Institutional opioid prescription data were supplied by pharmacies at two academically affiliated health care facilities in the region, Dartmouth Hitchcock Medical Center (DHMC) and the University of Vermont Medical Center (UVMC). Opioid utilization per 1,000 adult patients was calculated based on the estimated 2014 United States census (Table 5 ).
Noninjectable opioid prescriptions captured from the NPA database were divided into three therapeutic classes (TCs): codeine and codeine combinations, morphine/opium, and synthetic opioid analgesics. Percent market share was calculated for drugs with greater than 5% market share in their particular TC. Number of prescriptions in each TC were totaled, allowing for calculation of percent change of each TC and drug between 2013 and 2014.
Long-acting or extended-release (LA/ER) opioid formulations were defined as those designed to be taken two to three times per day. This comprised of 10 total opioid analgesics, including methadone (Table 6 ). Buprenorphine products were not included in this list.
Statistical analysis: Opioid utilization per 1,000 adult patients was calculated based on the estimated 2014 United States census (Table 5 ) [21] . We used a chisquare distribution to assess for statistical significance of the national and state-wide changes in opioid prescriptions, and P values were calculated based on one degree of freedom using the UCLA School of Medicine Statistical Online Computational Resource [22] .
Data used in this study were both de-identified and publically available. The study was approved by the Dartmouth Hitchcock Medical Center Committee for the Protection of Human Subjects.
Results
The total number of opioid prescriptions decreased nationally by 3.4% (P ¼ 0.81) between January and June 2013 and July and December 2014 (Table 1) . This was driven largely by a 6.6% decrease in the codeine and combination TC, yet offset by a 9.2% increase in the Opioid Prescribing Patterns, 2013-14 smaller synthetic opioid group, of which tramadol and methadone comprise 91% (Table 2) . Prescriptions in the morphine/opium TC remained stable over the two-year study, dropping by only 0.3%. Overall the number of opioid prescriptions in the United States per 1,000 citizens decreased from 85.0 to 82.1 ( Figure 1 ).
Three of the four New England states in the study (VT, MA, ME) have shown a decline in opioid prescribing, the largest of which was seen in Maine (-5.2%, P ¼ 0.72), followed by Massachusetts (-4.4%, P ¼ 0.78) and Vermont (-2.2%, P ¼ 0.89). While New Hampshire was the only state to see an increase in prescribing (þ1.3%, P ¼ 0.94), it had the lowest number of prescriptions per 1,000 residents (51, compared with 66.2, 67, and 81 in MA, VT, and ME, respectively). Across the three therapeutic classes, codeine and combination prescriptions decreased in all states (-8.9%, -7.0%, -6.4%, and -3.1% in ME, MA, VT, and NH, respectively), while synthetic opioid prescriptions rose (þ17.2%, þ6.9%, þ5.0%, and þ4.9% in NH, MA, VT, and ME, respectively). Drugs in the morphine/opium TC also increased in all four states (þ7.7%, þ6.5%, þ5.2%, and þ0.8% in NH, VT, ME, and MA, respectively).
Opioid prescriptions filled through the UVMC pharmacy declined by 13.6%, a significant change compared with the 0.4% decrease seen at DHMC (Table 3) . At UVMC, total prescriptions in all three therapeutic classes declined. Individual opioids contributing to this decline (from greatest to least market share) included oxycodone (-5.5%), hydromorphone (-11%), and hydrocodone (-30.1%) ( Table 4) . Although individual drug data was not available from DHMC, none of the therapeutic classes here changed by over 1%.
Opioid analgesics representing greater than 5% market share were identified in each TC nationally and by state ( Table 2) . Table 5 ).
Nationally, hydrocodone/APAP represented 59.3% market share of the codeine and combination TC, and 43.4% of all opioids. Opioid Prescribing Patterns, 2013-14 by 14.8%, from 16.9 to 19 million over the study period. Likewise tramadol has seen an increase in all four states studied, as high as 22.7% in New Hampshire. Methadone, at 6.8% market share of this TC and only 1.3% overall, decreased by 11.8%. Methadone prescribing also decreased in three of the four New England states (VT, MA, ME), but was up 1.9% in New Hampshire.
Nationally, MSIR represented 44.6% market share in the morphine/opium TC and 3.4% overall. This was followed by fentanyl (25.9% of this TC, 2% overall) and hydromorphone (16.4% of this TC, 1.3% overall). Three out of four New England states (NH, VT, ME) saw an increase in prescribing of these three drugs, whereas no clear pattern was evident in Massachusetts or nationally.
LA/ER opioids (Table 6 ) accounted for 4.3% of the total 120.5 million opioid prescriptions filled nationally between July and December 2014.
Discussion
The results here demonstrate no statistically significant change in opioid prescription numbers on a national, state, or institutional level from 2013-14. This is suggestive of a plateauing of the previously upward trajectory seen between the late 1990s and 2010. An examination of individual opioid analgesics revealed a 13% decrease in hydrocodone/APAP prescribing, 3.9% increase in oxycodone, 12.7% increase in codeine/ APAP, 14.8% increase in tramadol, 12% decrease in methadone, 2% increase in MSIR, 2% decrease in fentanyl, and 1% decrease in hydromorphone. Hydrocodone products comprise the largest percent market share of all opioids prescribed from July to December 2014 (excluding buprenorphine products); thus its decline had the largest impact on the overall picture of opioid prescribing nationally.
The timing of our study was unique in the fact that hydrocodone had been reclassified from a schedule III to II drug by the US Drug Enforcement Agency in August 2014. This likely had a significant impact on prescribing rates of the drug in the second half our study period. As a schedule III drug prior to August 2014, hydrocodone was by definition of "moderate to low potential for physical and psychological dependence" [23] .
In reality, hydrocodone is in the top three of prescription opioid-related deaths, just below schedule II methadone and oxycodone [24] . Prescribing of hydrocodone dropped precipitously in July-December 2014, down as low as 15% in Massachusetts and Maine, and 31.5% from the UVMC pharmacy. Tramadol and oxycodone continued to rise nationally; this may be a continuation of their previously documented upward trends [8, 25] , a shift of prescribing from hydrocodone to these agents, or both. Tramadol, a weak mu opioid receptor agonist, is likely gaining traction due to less abuse potential (schedule IV as of August 2014) and fewer overdose deaths compared with pure opioid agonists [26, 27] .
Other contributors to the potential leveling of prescription opioid drug utilization include efforts put forth by federal and state-based programs. For example, educational curricula designed by the National Institute on Drug Abuse (NIDA) and Office of National Drug Control Policy (ONDCP) target providers at all levels of training to improve knowledge on drug abuse, addiction, and safe opioid prescribing [28, 29] . Surratt et al. was able to demonstrate declines in opioid diversion following a two-year implementation of a prescription drug monitoring program (PDMP) and legislation to better regulate pain clinic prescribing practices in Florida [30, 31] . Daily morphine equivalent doses in Washington workers compensation patients declined by 27% in the four years following release of an opioid dosing guideline educational pilot [32] . Availability of opioid addiction treatment is robust in Vermont, where "Vermont buprenorphine practice guidelines" [33] empower primary care providers to seek necessary training in opioid addiction.
LA/ER opioid formulations comprised 4.3% of the nation's opioid prescriptions in 2014. This contrasts with a CDC report in 2012 showing a 12.5% prevalence of LA/ ER opioids that year [34] , which utilized the same database and a similar definition of LA/ER formulations. This comparison suggests that providers may be shifting away from prescribing these types of high-risk medications. Of note, the Food and Drug Administration (FDA) launched a risk management program for prescribers of LA/ER opioids in 2012, with educational classes made available in 2013 [35] . This was followed in 2013 with the FDA restriction of LA/ER opioids to patients with a diagnosis of "severe" pain only [36] , potentially limiting the number of LA/ER formulations covered by thirdparty insurers. Further research is necessary to confirm the impact this strategy has had on prescribing practices and to further clarify long-term trends in LA/ER opioid medications.
Prescription drug monitoring programs (PDMPs) have already demonstrated a positive impact on identifying patients who "doctor shop" for high-risk medications, enabling providers to prescribe scheduled drugs more responsibly [37] . Of the four New England states in our study, three had operational PDMPs (VT, ME, MA), while the New Hampshire PDMP was not active until September 2014. Interestingly, although not reaching statistical significance, Vermont, Maine, and Massachusetts saw declines in opioid prescribing whereas New Hampshire did not. Mandatory use of state PDMPs by providers is also suggested to improve their efficacy [38] ; Vermont and Massachusetts had such mandates, whereas New Hampshire and Maine did not.
Medical marijuana (MM) may also have a role in opioid prescribing rates in states with legislation. MM has been gaining support as an adjunct or even substitute for opioids in patients with chronic pain [39] . In a study out of a MM evaluation clinic in California, 82.6% were using cannabis for pain relief, and 50.8% as a substitute for prescription medication [40] . Currently 23 US states and Washington DC have laws regulating the use of MM, and previous work has shown that states with MM laws had a 24.8% lower mean annual opioid overdose mortality rate [41] . Through the duration of our study, only two of the four New England states (VT and ME) had operational MM dispensaries.
The decision to review institutional opioid utilization originated from NPA database results showing New Hampshire as the only state to observe an increase in prescribing and a desire to compare opioid prescribing at our home institution in New Hampshire (DHMC) to benchmark national and state data. Furthermore, by comparing DHMC to a geographically similar institution in Vermont (UVMC), we wished to establish a framework for future research projects and interventions in judicious opioid prescribing. This study has opened opportunities for collaboration with several providers at UVMC, and our data has been shared with hospital leadership, representatives from the New Hampshire Board of Medicine, and the New Hampshire Attorney General. Plans are underway to evaluate opioid use in DHMC patients with specific chronic disease diagnoses such as diabetic peripheral neuropathy, fibromyalgia, and rheumatoid arthritis, where our preliminary data show a high prevalence of opioid use. Additionally, we plan to evaluate opioid use by payer type to identify prescribing patterns relative to insurance regulations, drug cost, etc.
This study was subject to several important limitations. We did not obtain month-to-month prescription information from the NPA database, limiting our ability to perform a trend analysis over the study period. The NPA database could neither identify diagnoses linked to the prescription, nor which prescriptions are refills for the same patient. Opioids for acute, postoperative, cancerrelated, or chronic noncancer pain could not be distinguished from one another. There was no identification of prescriptions by gender, age, or payer type. Medication adherence could not be assessed. We used the US census for adults over 18 years of age for our calculations; however, the database did not exclude any opioids for pediatric patients; this would likely have had marginal impact on our data. We also did not account for any differences in opioid prescribing related to seasonal variation between January-June and JulyDecember. We are unable to ascertain whether the inflections in opioid prescriptions seen are resulting from decreased supply-fewer providers prescribing the drug-or decreased demand-fewer patients requesting opioid analgesics.
Conclusions
The evolution of prescription opioid addiction, diversion, misuse, abuse, and overdose deaths since the late 1990s has led to drug reforms at federal, state, and institutional levels. Our analysis of the NPA database has expanded upon current knowledge of opioid use in America. While this data suggests a subtle decline in prescription opioid utilization nationally, regional data from northern New England suggests that states with functional PDMPs, medical marijuana legislation, and robust opioid addiction treatment may be seeing lower opioid prescribing compared with states without. The review of prescription opioid use at our home academic institution has prompted a discussion with hospital and state government officials and spawned further research efforts aiming to optimize judicious opioid prescribing. The authors strongly recommend that other institutions review their own opioid usage with similar goals in mind.
